Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

Plinabulin plus docetaxel survival and safety results support second- or third-line use in non-small-cell lung cancer patients with wild-type EGFR after platinum-based chemotherapy

Ipilimumab–nivolumab given every 12 weeks, instead of every 3 weeks, reduces toxicities in patients with treatment-naïve advanced renal cell carcinoma without compromising efficacy

The CAPTURE study has characterised functional immune responses in people with cancer following SARS-CoV-2 infection or vaccination

People with colorectal cancer liver cancer metastases that have progressed may benefit from second-line trans-arterial Yttrium-90 radioembolisation

Most solid tumour patients recently given chemotherapy and/or immunotherapy will achieve an adequate antibody response to COVID-19 vaccination

Study findings suggest that drug-free intervals during sunitinib or pazopanib treatment may be acceptable for patients with advanced clear cell renal cell carcinoma

Combining osimertinib with bevacizumab has not improved the outcomes of advanced nonsquamous non-small-cell lung cancer patients with EGFR activating mutations

Children and adults with PIK3CA-related overgrowth spectrum experienced improvements in lesions and symptoms following treatment with alpelisib